.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
UBS
Colorcon
Johnson and Johnson
Fish and Richardson
Express Scripts
Cerilliant
Queensland Health
Julphar

Generated: December 14, 2017

DrugPatentWatch Database Preview

LYNPARZA Drug Profile

« Back to Dashboard

Which patents cover Lynparza, and when can generic versions of Lynparza launch?

Lynparza is a drug marketed by Astrazeneca Pharms and is included in two NDAs. There are eight patents protecting this drug.

This drug has two hundred and sixty-five patent family members in forty-eight countries and twelve supplementary protection certificates in eleven countries.

The generic ingredient in LYNPARZA is olaparib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the olaparib profile page.

Summary for LYNPARZA

Drug patent expirations by year for LYNPARZA

Pharmacology for LYNPARZA

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-002Aug 17, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-002Aug 17, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsLYNPARZAolaparibCAPSULE;ORAL206162-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-002Aug 17, 2017RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsLYNPARZAolaparibCAPSULE;ORAL206162-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-002Aug 17, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsLYNPARZAolaparibCAPSULE;ORAL206162-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-001Aug 17, 2017RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Astrazeneca PharmsLYNPARZAolaparibCAPSULE;ORAL206162-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-001Aug 17, 2017RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: LYNPARZA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,351,701Therapeutic compounds► Subscribe
7,750,006Phthalazinone derivatives► Subscribe
9,169,235Phthalazinone derivatives► Subscribe
9,566,276Phthalazinone derivatives► Subscribe
8,071,579DNA damage repair inhibitors for the treatment of cancer► Subscribe
7,531,530Therapeutic compounds► Subscribe
7,662,818Phthalazinone derivatives► Subscribe
7,692,006Phthalazinone derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LYNPARZA

Country Document Number Estimated Expiration
Israel211809► Subscribe
Spain2372630► Subscribe
Japan2014001210► Subscribe
Japan2012087135► Subscribe
Denmark1330442► Subscribe
Japan2006528618► Subscribe
Japan5607773► Subscribe
TaiwanI338000► Subscribe
Canada2737400► Subscribe
South Africa200601386► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LYNPARZA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/016Ireland► SubscribePRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
0150012 00136Estonia► SubscribePRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
680Luxembourg► SubscribePRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218
90019-4Sweden► SubscribePRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218
/2015Austria► SubscribePRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
2015016Lithuania► SubscribePRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216
C0022France► SubscribePRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218
3 50005-2015Slovakia► SubscribePRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218
2015 00012Denmark► SubscribePRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216
500012Hungary► SubscribePRODUCT NAME: OLAPARIB
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Deloitte
Healthtrust
Federal Trade Commission
Cipla
Cantor Fitzgerald
Farmers Insurance
UBS
Chinese Patent Office
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot